Impact of Cushing's syndrome on the gonadotrope axis and testicular functions in men

被引:9
|
作者
Papadakis, Georgios E. [1 ,2 ,3 ]
de Kalbermatten, Benedicte [2 ]
Dormoy, Alexandre [2 ]
Salenave, Sylvie [2 ]
Trabado, Severine [4 ]
Vieira-Pinto, Oceana [2 ]
Richa, Carine [2 ]
Kamenicky, Peter [2 ,5 ,6 ]
Chanson, Philippe [2 ,5 ,6 ]
Maione, Luigi [2 ,5 ,6 ]
Pitteloud, Nelly [1 ,3 ]
Young, Jacques [2 ,5 ,6 ,7 ]
机构
[1] Lausanne Univ Hosp, Serv Endocrinol Diabet & Metab, Lausanne, Switzerland
[2] Paris Saclay Univ, Bicetre Hosp, Assistance Publ Hop Paris, Dept Reprod Endocrinol,Reference Ctr Rare Pituitar, Le Kremlin Bicetre, France
[3] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland
[4] CHU Bicetre, Hop Univ Paris Saclay, Assistance Publ Hop Paris, Serv Genet Mol Pharmacogenet & Hormonol, Le Kremlin Bicetre, France
[5] Paris Saclay Med Sch, INSERM UMR S 1185, Le Kremlin Bicetre, France
[6] Univ Paris Saclay, Orsay, France
[7] Hop Bicetre, Serv Endocrinol Adultes, Batiment Barre Sinoussi,78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France
关键词
Cushing; hypogonadotropic hypogonadism; sperm count; testosterone; inhibin B; INSL3; infertility; ectopic ACTH syndrome; CONGENITAL HYPOGONADOTROPIC HYPOGONADISM; ANTI-MULLERIAN HORMONE; DIFFERENT MODALITIES; INHIBIN-B; DISEASE; TESTOSTERONE; SECRETION; COMPLICATIONS; DIAGNOSIS;
D O I
10.1093/humrep/dead187
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION Does Cushing's syndrome (CS) differently affect the gonadotrope axis and testicular functions (GA/TF) according to the hypercortisolism intensity and underlying etiology?SUMMARY ANSWER Endogenous cortisol excess caused by CS leads to varying degrees of hypogonadotropic hypogonadism (HH) with more severe GA/TF impairment and altered spermatogenesis in men with intense hypercortisolism associated with paraneoplastic/ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS).WHAT IS KNOWN ALREADY CS is very rarely studied in men due to its lower prevalence in men than in women. In a few old reports focusing exclusively on a limited number of men with Cushing's disease (CD), the occurrence of hypogonadism was reported. However, a detailed assessment of the impact of CS on the GA/TF in a significant series of patients has not been performed. Yet, hypogonadism could worsen CS-associated comorbidities such as osteoporosis and myopathy. To date, the full spectrum of GA/TF impairment in men with CS of different etiologies and intensity remains unknown.STUDY DESIGN, SIZE, DURATION In this monocentric study, 89 men with CS diagnosed at a tertiary endocrine university center (Bicetre, Paris Saclay) between January 1990 and July 2021 were evaluated and compared to 40 normal men of similar age.PARTICIPANTS/MATERIALS, SETTING, METHODS The CS patient cohort of 89 men included 51 with CD, 29 with EAS and 9 with CS of adrenal origin i.e. (ACTH-independent CS (AI-CS)). They all had frank hypercortisolism, with increased 24 h-urinary-free cortisol (24 h-UFC) in two separate samples. A case-control study was performed focusing on pituitary gonadotrope function and testicular sex steroids and peptides. An additional set of six CS men had an evaluation including semen analysis. In a subgroup of 20 men with available data after CS remission, a longitudinal analysis was conducted to assess the reversibility of GA/TF defects.MAIN RESULTS AND THE ROLE OF CHANCE Compared to controls, men with CS had significantly lower total testosterone (TT), bioavailable TT, and free TT (P < 0.0001). Hypogonadism, defined as serum TT levels <3.0 ng/ml, was present in 83% of men with EAS, in 61% of men with CD, and in 33% of men with AI-CS. Low-normal LH concentrations in the included men with hypercortisolism indicated HH. Serum sex hormone-binding globulin levels were moderately decreased in men with CD (P = 0.01 vs controls). Among the CS men, those with EAS had significantly lower TT, LH, and FSH levels than those with CD or AI-CS. When compared to controls, patients with EAS were the only group exhibiting a significant decrease in both serum FSH (P = 0.002) and the testicular peptides inhibin B (P < 0.0001) and anti-Mullerian hormone (P = 0.003). Serum INSL3 levels were significantly lower in men with CD than in the controls (P = 0.03). Of note, 24 h-UFC and ACTH were inversely and significantly associated with the majority of reproductive hormones including LH, FSH, TT, and inhibin B. Following successful curative therapy, reproductive assessment at a mean of 6.0 & PLUSMN; 4.3 years showed a significant increase in serum TT (P < 0.0001) and plasma LH (P = 0.02) levels, indicating a reversal of HH in 75% of the affected males. Among the six patients with available semen analysis, the two EAS cases exhibited a decrease in Sertoli cell peptides associated with a severe oligozoospermia, which completely normalized following removal of the source of hypercortisolism. LIMITATIONS, REASONS FOR CAUTION The potential bias due to the retrospective design is counteracted by the analysis of the largest male CS cohort to date as well as the use of stringent inclusion and exclusion criteria. Due to the low number of patients with semen analysis in this study, further research is needed to unravel the full spectrum of spermatogenesis defects in men with CS.WIDER IMPLICATIONS OF THE FINDINGS This work reveals the variable spectrum of reproductive impact in men with CS. We demonstrate that GA/TF impairment depends on the intensity of hypercortisolism which in turn is related to the underlying etiology. The causal link between hypercortisolism and GA/TF impairment was attested by its reversibility in most patients after CS remission. The wider implications of our findings lie in the potential generalization to a much commoner entity, iatrogenic CS due to chronic exposure to exogenous glucocorticoids.STUDY FUNDING/COMPETING INTEREST(S) Several research grants were attributed to J.Y.: (i) a grant from Programme Hospitalier de Recherche Clinique (PHRC # P081212 HYPOPROTEO); (ii) a grant from the French Association of Patients with Adrenal Diseases ('Association surrenales'); and (iii) independent Investigator Research Grants from HRA Pharma, Novartis and Recordati Pharma. A SICPA Foundation grant (Lausanne, Switzerland) allowed protected research time for G.E.P. The above sponsors were not involved in any part of the study. The authors have no competing or other conflicts of interest to declare.TRIAL REGISTRATION NUMBER N/A.
引用
收藏
页码:2350 / 2361
页数:12
相关论文
共 50 条
  • [1] Growth hormone axis in Cushing's syndrome
    Wajchenberg, BL
    Liberman, B
    Neto, DG
    Morozimato, MY
    Semer, M
    Bracco, LO
    Salgado, LR
    Knoepfelmacher, M
    Borges, MHS
    Pinto, ACAR
    Kater, CE
    Lengyel, AMJ
    HORMONE RESEARCH, 1996, 45 (1-2) : 99 - 107
  • [2] Asymptomatic pheochromocytoma associated with MEN syndrome and subclinical Cushing's syndrome
    Shah, Sanjit Kumar
    Tiwari, Mahipendra
    Acharya, Sneh
    Shah, Avish
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2023, 108
  • [3] Morbidity of Cushing's Syndrome and Impact of Treatment
    Webb, Susan M.
    Valassi, Elena
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (02) : 299 - +
  • [4] AGING OF THE HYPOTHALAMOPITUITARY TESTICULAR AXIS IN MEN
    VERMEULEN, A
    KAUFMAN, JM
    HORMONE RESEARCH, 1995, 43 (1-3) : 25 - 28
  • [5] Cushing's syndrome: more than physical impact
    Ribeiro, A. M.
    Peixoto, M. J.
    Oliveira, M.
    Costa, A.
    Coelho, R.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 : 60 - 60
  • [6] Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease
    Salenave, Sylvie
    Bernard, Valerie
    Do Cao, Christine
    Guignat, Laurence
    Bachelot, Anne
    Leboulleux, Sophie
    Droumaguet, Celine
    Bry-Gauillard, Helene
    Pierre, Peggy
    Criniere, Lise
    Santulli, Pietro
    Touraine, Philippe
    Chanson, Philippe
    Schlumberger, Martin
    Maiter, Dominique
    Baudin, Eric
    Young, Jacques
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) : 141 - 149
  • [7] Cushing's Disease in a Patient with MEN 2B Syndrome
    Kruljac, Ivan
    Dabelic, Nina
    Marjan, Domagoj
    Blaslov, Kristina
    Peric, Bozidar
    Mirosevic, Gorana
    Vagic, Davor
    Vrkljan, Milan
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (02): : E46 - E47
  • [8] Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome
    Giordano R.
    Picu A.
    Broglio F.
    Bonelli L.
    Baldi M.
    Berardelli R.
    Ghigo E.
    Arvat E.
    Pituitary, 2004, 7 (4) : 243 - 248
  • [9] NEUROENDOCRINE AXIS OF STRESS, METABOLIC SYNDROME AND PSYCHIATRIC DISORDERS IN CUSHING'S SINDROME
    Londono, Federico Uribe
    Franco, Juliana Gomez
    Franco, Luisa Fernanda Mesa
    Tobon, Leidy Alexandra Lezcano
    IATREIA, 2005, 18 (04) : 431 - 445
  • [10] Topical Steroids Inducing Cushing's Syndrome and Subsequent Adrenal Axis Suppression
    Francis, Innocent E.
    Seedahmed, Khalid
    Khumalo, Nonhlanhla
    Ross, Ian Louis
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2019, 9 (03) : 629 - 632